Home › Companies › Arcutis Biotherapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2026: 5 items on Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026: 5 passed (calculated).
Significant dissent: 1 director (32.6% against).
Notable dissent: 2 directors (19.6%, 18.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 6.7%, as of September 30, 2026)
Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Patrick J. Heron | 62,830,439 | -- | -- | 30,446,098 | 14,868,017 | 67% | Passed (calculated) | — |
| Elect Director: Neha Krishnamohan | 74,956,903 | -- | -- | 18,319,634 | 14,868,017 | 80% | Passed (calculated) | — |
| Elect Director: Todd Franklin Watanabe | 75,771,853 | -- | -- | 17,504,684 | 14,868,017 | 81% | Passed (calculated) | — |
| 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 | 107,867,442 | 15,748 | 261,364 | -- | -- | 99.9% | Passed (calculated) | — |
| 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers | 88,728,269 | 3,723,408 | 824,860 | -- | 14,868,017 | 96% | Passed (calculated) | — |
Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
305 asset managers disclosed a vote on at least one Arcutis Biotherapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Neha Krishnamohan
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Neha Krishnamohan”): 74,956,903 for, 18,319,634 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 26,182,809 for, 4,712,901 withheld, 50 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,849,997 | 0 | 50 | 55,434 | For |
| State Street | 3,804,213 | 0 | 0 | 4,442 | For |
| BlackRock | 3,277,010 | 0 | 0 | 0 | For |
| Fidelity | 2,954,046 | 0 | 0 | 53,100 | For |
| Prudential/PGIM | 2,217,792 | 0 | 0 | 3,298 | For |
| OBERWEIS FUNDS | 0 | 0 | 0 | 1,211,800 | Withhold |
| American Century | 0 | 0 | 0 | 1,120,551 | Withhold |
| Charles Schwab | 1,012,955 | 0 | 0 | 0 | For |
| TIAA | 870,242 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 850,058 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 710,000 | 0 | 0 | 0 | For |
| Federated Hermes | 689,843 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 396,980 | Withhold |
| First Trust | 0 | 0 | 0 | 351,058 | Withhold |
| Bridge Builder Trust | 334,408 | 0 | 0 | 0 | For |
| T. Rowe Price | 281,489 | 0 | 0 | 0 | For |
| Equitable | 156,363 | 0 | 0 | 74,380 | Mixed |
| AMG FUNDS | 230,038 | 0 | 0 | 0 | For |
| Jackson National | 147,000 | 0 | 0 | 56,192 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 179,784 | Withhold |
| BUFFALO FUNDS | 173,306 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 163,367 | Withhold |
| Lincoln Financial | 74,800 | 0 | 0 | 68,824 | Mixed |
| Allspring | 0 | 0 | 0 | 132,842 | Withhold |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
67% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Patrick J. Heron
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Patrick J. Heron”): 62,830,439 for, 30,446,098 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 22,200,421 for, 8,695,256 withheld, 83 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,849,964 | 0 | 83 | 55,434 | For |
| State Street | 7,680 | 0 | 0 | 3,800,975 | Withhold |
| BlackRock | 3,277,010 | 0 | 0 | 0 | For |
| Fidelity | 2,954,046 | 0 | 0 | 53,100 | For |
| Prudential/PGIM | 2,217,792 | 0 | 0 | 3,298 | For |
| OBERWEIS FUNDS | 0 | 0 | 0 | 1,211,800 | Withhold |
| American Century | 0 | 0 | 0 | 1,120,551 | Withhold |
| Charles Schwab | 1,012,955 | 0 | 0 | 0 | For |
| TIAA | 870,242 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 850,058 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 710,000 | 0 | 0 | 0 | For |
| Federated Hermes | 689,843 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 396,980 | Withhold |
| First Trust | 0 | 0 | 0 | 351,058 | Withhold |
| Bridge Builder Trust | 334,408 | 0 | 0 | 0 | For |
| T. Rowe Price | 281,489 | 0 | 0 | 0 | For |
| Equitable | 156,363 | 0 | 0 | 74,380 | Mixed |
| AMG FUNDS | 230,038 | 0 | 0 | 0 | For |
| Jackson National | 147,000 | 0 | 0 | 56,192 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 179,784 | Withhold |
| BUFFALO FUNDS | 173,306 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 163,367 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 143,624 | Withhold |
| Allspring | 0 | 0 | 0 | 132,842 | Withhold |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Todd Franklin Watanabe
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Todd Franklin Watanabe”): 75,771,853 for, 17,504,684 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 26,332,327 for, 4,563,385 withheld, 48 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,849,999 | 0 | 48 | 55,434 | For |
| State Street | 3,804,213 | 0 | 0 | 4,442 | For |
| BlackRock | 3,277,010 | 0 | 0 | 0 | For |
| Fidelity | 2,954,046 | 0 | 0 | 53,100 | For |
| Prudential/PGIM | 2,217,792 | 0 | 0 | 3,298 | For |
| OBERWEIS FUNDS | 0 | 0 | 0 | 1,211,800 | Withhold |
| American Century | 0 | 0 | 0 | 1,120,551 | Withhold |
| Charles Schwab | 1,012,955 | 0 | 0 | 0 | For |
| TIAA | 870,242 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 850,058 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 710,000 | 0 | 0 | 0 | For |
| Federated Hermes | 689,843 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 396,980 | Withhold |
| First Trust | 0 | 0 | 0 | 351,058 | Withhold |
| Bridge Builder Trust | 334,408 | 0 | 0 | 0 | For |
| T. Rowe Price | 281,489 | 0 | 0 | 0 | For |
| Equitable | 230,743 | 0 | 0 | 0 | For |
| AMG FUNDS | 230,038 | 0 | 0 | 0 | For |
| Jackson National | 147,000 | 0 | 0 | 56,192 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 179,784 | Withhold |
| BUFFALO FUNDS | 173,306 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 163,367 | Withhold |
| Lincoln Financial | 74,800 | 0 | 0 | 68,824 | Mixed |
| Allspring | 0 | 0 | 0 | 132,842 | Withhold |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 84.7% for (June 12, 2025 meeting) ▲ 11.3 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 88,728,269 for, 3,723,408 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,905,472 | 6 | 3 | 0 | For |
| State Street | 3,808,655 | 0 | 0 | 0 | For |
| BlackRock | 3,277,010 | 0 | 0 | 0 | For |
| Fidelity | 3,007,146 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,221,090 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 1,211,800 | 0 | 0 | 0 | For |
| American Century | 0 | 1,120,551 | 0 | 0 | Against |
| Charles Schwab | 1,012,955 | 0 | 0 | 0 | For |
| TIAA | 870,242 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 850,058 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 710,000 | 0 | 0 | 0 | For |
| Federated Hermes | 689,843 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 396,980 | 0 | 0 | 0 | For |
| First Trust | 351,058 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 334,408 | 0 | 0 | 0 | For |
| T. Rowe Price | 281,489 | 0 | 0 | 0 | For |
| Equitable | 230,743 | 0 | 0 | 0 | For |
| AMG FUNDS | 230,038 | 0 | 0 | 0 | For |
| Jackson National | 203,192 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 179,784 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 173,306 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 163,367 | 0 | 0 | 0 | For |
| Lincoln Financial | 143,624 | 0 | 0 | 0 | For |
| Allspring | 132,842 | 0 | 0 | 0 | For |
Fund voting reports, all 87 managers: 29,665,630 for, 1,218,642 against, 11,166 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 11,785,519 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 10,719,320 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 9,874,511 | 0 | 0 | 0 | For |
| State Street | 6,184,113 | 3,852 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 4,294,741 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 4,151,354 | 0 | 0 | 0 | For |
| BlackRock | 3,670,107 | 656 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,047,912 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,270,457 | 0 | 0 | 0 | For |
| OBERWEIS ASSET MANAGEMENT INC/ | 1,365,941 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 1,244,387 | 0 | 0 | 0 | For |
| American Century | 0 | 1,242,708 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,179,449 | 0 | 0 | 0 | For |
| Janus Henderson | 1,135,958 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 1,086,651 | 0 | 0 | Against |
| Federated Hermes | 1,059,299 | 0 | 0 | 0 | For |
| Charles Schwab | 1,013,136 | 0 | 0 | 0 | For |
| DE Shaw | 986,579 | 0 | 0 | 0 | For |
| BAMCO INC /NY/ | 930,000 | 0 | 0 | 0 | For |
| Vanguard | 927,750 | 0 | 0 | 0 | For |
| Nuveen | 900,216 | 0 | 0 | 0 | For |
| Northern Trust | 852,062 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 794,211 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 686,616 | 0 | 0 | 0 | For |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 676,200 | 0 | 0 | 0 | For |
Institutional-manager reports, all 241 managers: 79,587,267 for, 2,981,555 against, 59 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Prior year: 100.0% for (June 12, 2025 meeting) unchanged
Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 107,867,442 for, 15,748 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 30,884,596 for, 11,164 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,905,480 | 0 | 1 | 0 | For |
| State Street | 3,808,655 | 0 | 0 | 0 | For |
| BlackRock | 3,277,010 | 0 | 0 | 0 | For |
| Fidelity | 3,007,146 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,221,090 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 1,211,800 | 0 | 0 | 0 | For |
| American Century | 1,120,551 | 0 | 0 | 0 | For |
| Charles Schwab | 1,012,955 | 0 | 0 | 0 | For |
| TIAA | 870,242 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 850,058 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 710,000 | 0 | 0 | 0 | For |
| Federated Hermes | 689,843 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 396,980 | 0 | 0 | 0 | For |
| First Trust | 351,058 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 334,408 | 0 | 0 | 0 | For |
| T. Rowe Price | 281,489 | 0 | 0 | 0 | For |
| Equitable | 230,743 | 0 | 0 | 0 | For |
| AMG FUNDS | 230,038 | 0 | 0 | 0 | For |
| Jackson National | 203,192 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 179,784 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 173,306 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 163,367 | 0 | 0 | 0 | For |
| Lincoln Financial | 143,624 | 0 | 0 | 0 | For |
| Allspring | 132,842 | 0 | 0 | 0 | For |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,042,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.52% |
| 2 | State Street | 3.05% |
| 3 | BlackRock | 2.62% |
| 4 | Fidelity | 2.40% |
| 5 | Prudential/PGIM | 1.78% |
| 6 | OBERWEIS FUNDS | 0.97% |
| 7 | American Century | 0.90% |
| 8 | Charles Schwab | 0.81% |
| 9 | TIAA | 0.70% |
| 10 | FRANKLIN STRATEGIC SERIES | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 9.43% |
| 2 | Polar Capital Holdings Plc | 8.57% |
| 3 | Frazier Life Sciences Management, L.P. | 7.90% |
| 4 | State Street | 4.95% |
| 5 | JENNISON ASSOCIATES LLC | 3.43% |
| 6 | Rubric Capital Management LP | 3.32% |
| 7 | BlackRock | 2.94% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.44% |
| 9 | FRANKLIN ADVISERS INC | 1.82% |
| 10 | OBERWEIS ASSET MANAGEMENT INC/ | 1.09% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Suvretta Capital Management, LLC | 9,534,837 | 7.63% | Proxy statement (DEF 14A), table as of April 8, 2026 |
| BlackRock | 9,200,411 | 7.36% | Form 13F, quarter ended March 31, 2026 |
| Patrick J. Heron | 8,855,253 | 7.08% | Proxy statement (DEF 14A), table as of April 8, 2026 |
| Frazier Life Sciences VIII, L.P. | 8,785,284 | 7.03% | Proxy statement (DEF 14A), table as of April 8, 2026 |
| Rubric Capital Management LP | 8,271,577 | 6.62% | Schedule 13G, filed February 13, 2026 |
| Vanguard Group | 7,253,936 | 5.80% | Form 13F, quarter ended March 31, 2026 |
| State Street | 6,296,197 | 5.04% | Form 13F, quarter ended March 31, 2026 |
| PRUDENTIAL FINANCIAL INC | 5,302,713 | 4.24% | Schedule 13G, filed May 8, 2026 |
| Jennison Associates LLC | 4,980,770 | 3.98% | Schedule 13G, filed May 6, 2026 |
| Morgan Stanley | 4,340,239 | 3.47% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 125,042,000 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Arcutis Biotherapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 305 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,545 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Arcutis Biotherapeutics (ARQT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arcutis-biotherapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.